Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04526795CT.gov Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | — | Terminated | — | — | — |
NCT00005803CT.gov Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell Prolymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytarabine (this asset) | M.D. Anderson Cancer Center | P2 | BB · 70 |
| Cyclophosphamide | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | P2 | BB |
| Fludarabine | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | P3 | BB |
| Etoposide | Fred Hutchinson Cancer Center | P2 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
| Sirolimus | Fred Hutchinson Cancer Center | P3 | BB |
| Camustine | Fred Hutchinson Cancer Center | P2 | BB |
| Melphalan | Fred Hutchinson Cancer Center | P2 | BB |
| Ruxolitinib | Jonathan Brammer | P2 | B |
+20 more in the T-Cell Prolymphocytic Leukemia cohort
Other indications for Cytarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyBB
- FludarabineUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyBB
- EtoposideFred Hutchinson Cancer CenterBB
- Cyclosporin AFred Hutchinson Cancer CenterBB
- SirolimusFred Hutchinson Cancer CenterBB
Citation
Floatz Terminal. Cytarabine in T-Cell Prolymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cytarabine-t-cell-prolymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →